|
Cabrellis
Pharmaceuticals is a new, specialty
pharmaceutical company committed to the
development of important therapies for
the treatment of cancer. The Cabrellis
development program centers on Calsed™,
an exciting third generation synthetic
anthracycline drug currently approved
and commercialized for small-cell and
non-small-cell lung cancers in Japan.
Cabrellis holds the exclusive North
American and European development and
commercialization rights to this drug.
Cabrellis intends to develop Calsed™ for
small-cell lung cancer and to expand
development in a variety of other solid
tumors.
Cabrellis Pharmaceuticals raises $27.5
million in Series A funding.
Read more >> |
|
|
|
|
